• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Diltiazem HCL, Extended-Release Capsules

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Diltiazem HCL, Extended-Release Capsules

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    The Diltiazem Hydrochloride extended-release capsules, taken in 120 to 240 mg a day doses, are principally used to reduce high blood pressure (hypertension).

    According to the American Heart Association, high blood pressure in adults defined as a blood pressure greater than or equal to 140 mm Hg systolic pressure or greater than or equal to 90 mm Hg diastolic pressure. High blood pressure has been directly linked to increases in the risk of various heart and brain conditions such as coronary heart disease and stroke.

    While high blood pressure can occur in anyone, high risk groups include blacks, middle-aged and elderly adults, obese people, heavy drinkers, and women taking oral contraceptives.

    Clinical Results

    Clinical studies compared the Diltiazem HCL extended release capsules with the Diltiazem HCL tablets. The two forms of the drug were shown to have similar trends in half-life, despite the difference in absorption rate. It was found that 95% of the extended-release capsule is absorbed throughout the dosing interval. The capsules take effect within two to three hours and active effects are detected for 10 to 14 hours.

    Side Effects

    Common side effects include headache, drowsiness, swelling of feet and ankles, constipation, nausea, sudden weight gain, and fatigue.

    More serious, but less common side effects include, irregular or slow heartbeat, shortness of breath, and fatigue caused by heart failure.

    There may be some drug interactions between Diltiazem HCL and aspirin, beta-blockers, digitalis preparations, carbamazepine, cyclosporine, digoxin, lithium, oral diabetes agents, phenytoin, rifampin, cimetidine, fluvoxamine, or ranitidine.

    Warning

    Suddenly discontinuing use of this drug may cause serious health problems. Any discontinuance of the drug should be in gradual dosage reductions.

    Mechanism of Action

    Diltiazem interferes with the movement of calcium into heart muscle cells and the smooth muscle cells in the walls of the arteries. This action relaxes blood vessels (causing them to widen), which lowers blood pressure, increases the blood supply to the heart, and decreases the hearts overall workload. "from www.DiscoveryHealth.com"

    Literature References

    For a brief overview of the drug Diltiazem HCL, visit Yahoo! Health

    Visit the American Heart Association web site to find out more about the risks involved with high blood pressure.

    Additional Information

    Diltiazem Hydrochloride is also available in tablet form to relieve and control angina (chest pain associated with heart disease) and in injection form to correct cardiac arrhythmia (heartbeat irregularities).

    Approval Date: 2000-01-01
    Company Name: Biovail Laboratories
    Back to Listings

    Upcoming Events

    • 15Apr

      Five Telltale Signs You’re Ready for an Electronic TMF System

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    • 06May

      The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Clinical-Trial-Brainstorming

      FDA, Industry Tackle Problem of Including Older Adults in Trials

    • ClinicalTrialNetwork-360x240.png

      National Community-Based Research Network Would Improve Reach of Trials

    • Bottleneck-360x240.png

      Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Genetic Research and IBC Oversight Requirements

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing